title: [Skin reaction to OK-432 and its dosage for locoregional administration].
abstract: Establishment of optimal dosage of OK-432, a streptococcal preparation, was studied based on its skin test was studied. Locoregional immunotherapy using OK-432 was conducted for patients with malignant fluids. More OK-432 was administered to patients having a weaker skin reaction to OK-432 and less to those having a stronger one, corresponding to their redness diameter of skin reaction. There was a marked difference in OK-432-skin test among patients. Some patients with malignant fluids having small redness responded to the treatment after a large amount of OK-432, and others were well controlled by a smaller dosage of OK-432. It is suggested that OK-432-skin test may provide the optimal dosage for local treatment of malignant fluids.
authors.affiliation: Dept. of Surgery, Hiroshima University.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Noma
authors.forename: E
authors.initials: E
authors.lastname: Miyahara
authors.forename: M
authors.initials: M
authors.lastname: Funakoshi
authors.forename: I
authors.initials: I
authors.lastname: Takashima
authors.forename: H
authors.initials: H
authors.lastname: Kawami
authors.forename: A
authors.initials: A
authors.lastname: Sawamura
authors.forename: T
authors.initials: T
authors.lastname: Toge
mesh_terms: D001202:Ascitic Fluid / Q000209:etiology / Q000628:therapy*; D001943:Breast Neoplasms / Q000150:complications; D010478:Chemotherapy, Cancer, Regional Perfusion; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000150:complications*; D006801:Humans; D007167:Immunotherapy; D015552:Injections, Intralesional; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D010844:Picibanil / Q000008:administration & dosage*; D012867:Skin / Q000276:immunology*; D012882:Skin Tests
chemical_list: D010844:Picibanil